We are seeking partnerships with technology providers, health experts, distribution networks, media outlets, investment funds, and organizations interested in promoting preventive health at scale.

Yes. We evaluate providers in areas such as software development, data infrastructure, applied intelligence, blockchain ecosystems, crypto solutions, and natural health products that align with our vision of holistic wellness.

Yes. IlongTech opens the door to strategic investors who wish to support the global growth of the iLongevity product and its expansion into the international B2B and B2C market.

IlongTech is the company that develops, maintains, and expands the technology. iLongevity is the product: a preventive health platform based on algorithmic intelligence, scientific research, and continuous personalization.

Both. We work with local partners in strategic markets, but our focus is international. iLongevity already has a presence in Latin America, India, and European countries.

Currently, we are 100% focused on our own technologies, especially iLongevity. Only in exceptional cases—when an external project represents a clear strategic opportunity—do we consider collaboration. We do not undertake custom development unless it directly aligns with our vision.

Yes. We evaluate integrations with complementary technologies, services, or products that add value to the end user and align with our mission of holistic health.

We are prioritizing partnerships in AI applied to health, data science, digital health, preventive education, blockchain, and strategic communication.

You can contact us through the form on this page or reach out directly via our official channels. Each proposal is reviewed by our Strategic Development team.

Yes. iLongevity can be implemented as a preventive health tool in government programs, driving impact in public policy, budget efficiency, and improved quality of life.

Yes. We have a specialized Strategic Partnerships team that coordinates key participations, evaluates opportunities, and ensures mutual objectives are met.

We measure impact based on scalability, health outcomes, economic efficiency, improvements in well-being indicators, and operational sustainability. Each partnership defines its own metrics according to its scope and objectives.

iLongevity already has functional modules in field tests and a stable version ready for commercial deployment. Its architecture is scalable and adaptable to different markets and languages.

Our technology detects potential nutritional and hormonal imbalances, offering personalized action plans. We combine algorithmic intelligence and continuous support in a comprehensive approach that connects data, context, and purpose.

Health companies, insurers, governments, wellness-sector corporations, medical groups, laboratories, tech startups, and investment funds have shown interest in partnering with or implementing our solution.